{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:23:59Z","timestamp":1791509039949,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005111","name":"Copenhagen University Hospital Rigshospitalet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcf.2025.08.008","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T11:15:01Z","timestamp":1756120501000},"page":"998-1005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Severe hepatotoxicity is uncommon following the introduction of Elexacaftor\/Tezacaftor\/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0970-4077","authenticated-orcid":false,"given":"Christine","family":"H\u00f8jte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5742-6403","authenticated-orcid":false,"given":"Mette Frahm","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-0155","authenticated-orcid":false,"given":"Daniel","family":"Faurholt-Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne H\u00f8rby","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-6404","authenticated-orcid":false,"given":"Christian","family":"Leo-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-6766","authenticated-orcid":false,"given":"Thomas","family":"Bryrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2453-216X","authenticated-orcid":false,"given":"Majbritt","family":"Jeppesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-210X","authenticated-orcid":false,"given":"Hanne Vebert","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terese L.","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-5262","authenticated-orcid":false,"given":"Bibi Uhre","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jcf.2025.08.008_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"issue":"10408","key":"10.1016\/j.jcf.2025.08.008_bib0002","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet Lond Engl"},{"issue":"10212","key":"10.1016\/j.jcf.2025.08.008_bib0003","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"19","key":"10.1016\/j.jcf.2025.08.008_bib0004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jcf.2025.08.008_bib0005","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for Cystic Fibrosis Phe508del\u2013Gating and \u2013Residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2025.08.008_bib0006","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med Marts"},{"key":"10.1016\/j.jcf.2025.08.008_bib0007","first-page":"54","article-title":"Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators","volume":"50","author":"Eldredge","year":"2024","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jcf.2025.08.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","author":"Tewkesbury","year":"2023","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"3","key":"10.1016\/j.jcf.2025.08.008_bib0009","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.japh.2023.02.015","article-title":"Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor","volume":"63","author":"Wood","year":"2023","journal-title":"J Am Pharm Assoc JAPhA"},{"issue":"4","key":"10.1016\/j.jcf.2025.08.008_bib0010","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.jcf.2025.08.008_bib0011","article-title":"Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor\/Tezacaftor\/Ivacaftor (Kaftrio)","volume":"34","author":"Salehi","year":"2021","journal-title":"Respir Med Case Rep"},{"issue":"2","key":"10.1016\/j.jcf.2025.08.008_bib0012","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"17","key":"10.1016\/j.jcf.2025.08.008_bib0013","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcf.2025.08.008_bib0014","doi-asserted-by":"crossref","first-page":"00339","DOI":"10.1183\/23120541.00339-2024","article-title":"Lung function improvement on triple modulators: high-resolution, nationwide data from the Danish Cystic Fibrosis Cohort","volume":"10","author":"Leo-Hansen","year":"2024","journal-title":"ERJ Open Res"},{"issue":"10","key":"10.1016\/j.jcf.2025.08.008_bib0015","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/apm.13453","article-title":"Real-world data confirm elexacftor\/tezacaftor\/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis","volume":"132","author":"Bryrup","year":"2024","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand oktober"},{"key":"10.1016\/j.jcf.2025.08.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/apm.13375","article-title":"Close monitoring and early intervention: management principles for cystic fibrosis in Denmark","author":"Qvist","year":"2024","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand"},{"key":"10.1016\/j.jcf.2025.08.008_bib0017","unstructured":"European Cystic Fibrosis Society. ECFS Patient Registry Annual Data Report 2022. 2022."},{"key":"10.1016\/j.jcf.2025.08.008_bib0018","article-title":"Lab values, normal adult: laboratory reference ranges in healthy adults","author":"Farinde","year":"2024","journal-title":"Medscape"},{"key":"10.1016\/j.jcf.2025.08.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2023.116809","article-title":"Pediatric reference values of alkaline phosphatase: analysis from a German population-based cohort and influence of anthropometric and blood parameters","volume":"174","author":"Strauch","year":"2023","journal-title":"Bone"},{"key":"10.1016\/j.jcf.2025.08.008_bib0020","article-title":"Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations","volume":"26","author":"Sellers","year":"2023","journal-title":"Hepatol Baltim Md"},{"issue":"3","key":"10.1016\/j.jcf.2025.08.008_bib0021","first-page":"136","article-title":"Liver disease in cystic fibrosis","volume":"9","author":"Kobelska-Dubiel","year":"2014","journal-title":"Przeglad Gastroenterol"},{"issue":"22","key":"10.1016\/j.jcf.2025.08.008_bib0022","doi-asserted-by":"crossref","first-page":"E8586","DOI":"10.3390\/ijms21228586","article-title":"Current treatment options for cystic fibrosis-related liver disease","volume":"21","author":"Staufer","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2025.08.008_bib0023","article-title":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","author":"Drummond","year":"2021","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"23","key":"10.1016\/j.jcf.2025.08.008_bib0024","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.3390\/jcm11236900","article-title":"Cystic fibrosis patients with F508del\/minimal function genotype: laboratory and nutritional evaluations after one year of Elexacaftor\/Tezacaftor\/Ivacaftor treatment","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2025.08.008_bib0025","article-title":"Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric Cystic Fibrosis","author":"Calvopina","year":"2021","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.008_bib0026","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/MPG.0000000000002872","article-title":"Extended screening for cystic fibrosis-related liver disease including elastography in children and adolescents","volume":"71","author":"H\u00f8jte","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2025.08.008_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor on liver fibrosis markers in adults with cystic fibrosis","author":"Tewkesbury","year":"2023","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"2","key":"10.1016\/j.jcf.2025.08.008_bib0028","doi-asserted-by":"crossref","first-page":"e0010","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol Commun Februar"},{"issue":"5","key":"10.1016\/j.jcf.2025.08.008_bib0029","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"18","key":"10.1016\/j.jcf.2025.08.008_bib0030","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.clinbiochem.2017.08.011","article-title":"Bilirubin concentration is positively associated with haemoglobin concentration and inversely associated with albumin to creatinine ratio among Indigenous Australians: eGFR Study","volume":"50","author":"Hughes","year":"2017","journal-title":"Clin Biochem"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:35:20Z","timestamp":1779953720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325015668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1569199325015668"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.08.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe hepatotoxicity is uncommon following the introduction of Elexacaftor\/Tezacaftor\/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}